Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) Non Operating Income (2024 - 2026)

Prelude Therapeutics' Non Operating Income history spans 3 years, with the latest figure at $3.8 million for Q1 2026.

  • On a quarterly basis, Non Operating Income rose 50.42% to $3.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.3 million, a 47.83% decrease, with the full-year FY2025 number at $5.1 million, down 59.59% from a year prior.
  • Non Operating Income hit $3.8 million in Q1 2026 for Prelude Therapeutics, up from $891000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for PRLD hit a ceiling of $5.1 million in Q4 2024 and a floor of $693000.0 in Q3 2025.
  • Historically, Non Operating Income has averaged $2.4 million across 3 years, with a median of $2.4 million in 2024.
  • Biggest five-year swings in Non Operating Income: plummeted 82.53% in 2025 and later surged 50.42% in 2026.
  • Tracing PRLD's Non Operating Income over 3 years: stood at $5.1 million in 2024, then plummeted by 82.53% to $891000.0 in 2025, then surged by 325.59% to $3.8 million in 2026.
  • Business Quant data shows Non Operating Income for PRLD at $3.8 million in Q1 2026, $891000.0 in Q4 2025, and $693000.0 in Q3 2025.